Thursday, April 2, 2020
09.00 Registration Opens
11.00 – 11.10 Welcome Address
Michael von Bergwelt
11.10 – 13.30 Plenary Symposium 1: Emerging Concepts / New Agents
Chair: Mario Sznol, Christoph Zielinski
11.10 - 11.30 Myeloid immune checkpoint inhibition
Timo K. van den Berg, Amsterdam, The Netherlands
11.30 - 11.50 Potential of ADAR Pathway in immunotherapy
Jeffrey Ishizuka, Boston, MA, USA
11.50 - 12.10 The Stimulator of Interferon Genes (STING) pathway. Emerging clinical data
Reinhard Dummer, Zurich, Switzerland
12.10 - 12.30 Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy
Christian Blank, Amsterdam, The Netherlands
12.30 - 12.50 CXCR3 required for anti-PD-1 efficacy
Melvyn Chow, Boston, MA, USA
12.50 - 13.10 IL-15 for cancer therapy
Mark Rubinstein, Charleston, SC, USA
13.10 - 13.30 T cell bispecific antibodies (4-1BB and tumor antigen)
Pablo Umana, Zurich, Switzerland
13.30 – 14.30 Lunch
14.30 – 16.10 Plenary Symposium 2: Microbiome and immunotherapy
Chair: Volkmar Nüssler, Giorgio Trinchieri
14.30 – 14.50 Microbiome and Immunotherapy in Cancer
Giorgio Trinchieri, Bethesda, MD, USA
14.50 - 15.10 Computational metagenomics for uncovering the unexplored microbiome diversity
Nicola Segata, Trento, Italy
15.10 - 15.30 Microbiome modulation for cancer therapy
Hendrik Poeck, Munich, Germany
15.30 - 15.50 Microbiome and epithelial cell stress in colon cancer
Dirk Haller, Munich, Germany
15.50 - 16.10 Microbiome modulation in HSC transplantation
Marcel van den Brink, New York, NY, USA
16.10 – 16.40 Coffee Break
16.40 – 19.10 Plenary Symposium 3: Tumor microenvironment
Chair: Paolo Ascierto, Eric Tartour
16.40 - 17.00 Cancer immunotherapy strategies based on overcoming barriers within the tumor
microenvironment
Tom Gajewski, Chicago, IL, USA
17.00 - 17.20 Immunoscore as possible predictive marker of response to treatments
Franck Pagès, Paris, France
17.20 - 17.40 Tumor intrinsic vs tumor extrinsic immune suppression
Kai Wucherpfennig, Boston, MA, USA
17.40 - 18.00 Arming oncolytic viruses for DC activation and recruitment in melanoma
T.D. de Gruijl, Amsterdam, The Netherlands
18.00 - 18.20 Dissecting the interplay between tumor cells and the immune system in melanoma progression and response to therapy
Marisol Soengas, Madrid, Spain
18.20 - 18.40 Pancreatic Cancer Tumor Microenvironment
Lei Zheng, Baltimore, MD, USA
18.40 - 18.55 Speaker 7 – from submitted abstracts
18.55 - 19.10 Speaker 8 – from submitted abstracts
19.10 – 22.00 Welcome Reception and Poster Viewing (at the venue)
Friday, April 3, 2020
08.30 – 09.30 Plenary Symposium 4: Vaccine Therapy
Chair: Barbara Seliger, Lei Zheng
08.30 - 08.50 Mucosal vaccinations for cancer treatment
Georg Stary, Vienna, Austria
08.50 - 09.10 Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma
Lisa Butterfield, San Francisco, CA, USA
09.10 - 09.30 Vaccine therapy in reversing anti -PD1 resistance
Samir Khleif, Washington, DC, USA
09.30 – 10.30 Pro & Contra Session:
Blinatumomab vs anti-CD19 CAR T cells: which treatment should be preferred and when?
Can we treat with either regimen after relapse on the other?
Chair: Wolfgang Herr
09.30 – 10.00 Pro Bite
Max Topp, Würzburg, Germany
10.00 – 10.30 Pro CAR
Marion Subklewe, Munich, Germany
10.30 – 11.00 Coffee Break
11.00 – 12.30 Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
Chair: Lisa Butterfield, José Saro
11.00 – 11.20 High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
Pier Federico Gherardini, San Francisco, CA, USA
11.20 – 11.40 Hyperprogressive disease in patients treated with Immune checkpoint inhibitors
Giuseppe Lo Russo, Milan, Italy
11.40 - 12.00 Novel splice isoforms, target for immunotherapy
Jacques Banchereau, Bar Harbor, ME, USA
12.00 – 12.15 Speaker 4 – from submitted abstracts
12.15 – 12.30 Speaker 5 – from submitted abstracts
12.30 – 14.00 Lunch
14.00 – 15.00 Satellite Symposium
15.00 – 15.45 Lifetime Achievement Award
Chair: Michael von Bergwelt
The 34th anniversary of interleukin 6; a major player in inflammation, autoimmunity and
cancer
Toshio Hirano, Chiba, Japan
15.45 – 16.15 Coffee Break
16.15 – 17.10 Plenary Symposium 6: “Lost in Translation”
Chair: Philipp Beckhove, Alfred Zippelius
16.15 – 16.35 Ups and downs of IDO inhibition in cancer treatment
George Prendergast, Philadelphia, PA, USA
16.35 – 16.55 Why adoptive T cell therapies fail solid tumors?
Sebastian Kobold, Munich, Germany
16.55 – 17.10 Speaker 3 – from submitted abstracts
17.10 – 18.10 Plenary Symposium 7: Young Researcher Session
Chair: Sebastian Kobold, Zihai Li
17.10 – 17.25 Speaker 1 - from submitted abstracts
17.25 – 17.40 Speaker 2 - from submitted abstracts
17.40 – 17.55 Speaker 3 - from submitted abstracts
17.55 - 18.10 Speaker 4 - from submitted abstracts
19.30 ITOC7 Conference Dinner
Saturday, April 4, 2020
08.00 – 09.05 Plenary Symposium 8: Cell Therapy in Solid Tumors
Chair: Christian Blank, Pedro Romero
08.00 – 08.20 Challenges of T-cell therapy in solid tumors
Cassian Yee, Houston, TX, USA
08.20 – 08.35 Novel CAR formats for solid tumors
Hidde Ploegh, Boston, MA, USA
08.35 – 08.50 Novel strategies to enable T cell therapy of cancer
Per Thor Straten, Herlev, Denmark
08.50 – 09.05 CAR T cell therapy in non hematological pediatric cancer
Franco Locatelli, Rome, Italy
09.05 – 10.20 Plenary Symposium 9: Cell Therapy in Haematologic Diseases
Chair: Florian Bassermann, Hinrich Abken
09.05 – 09.25 Cell therapy of hematological malignancies
Chiara Bonini, Milan, Italy
09.25 – 09.45 New targets and technologies for CAR-T
Michael Hudecek, Würzburg, Germany
09.45 – 10.05 Genome edited T cells for leukaemia
Waseem Quasim, London, United Kingdom
10.05 - 10.20 Speaker 4 – from submitted abstracts
10.20 – 10.50 Coffee Break
10.50 – 13.15 Plenary Symposium 10: Combination Therapy
Chair: Michael Bergmann, Samir Khleif
10.50 – 11.10 Combination of innate immune stimulation with immune check point blockade for
cancer therapy
Simon Heidegger, Munich, Germany
11.10 - 11.30 Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer
Marleen Kok, Amsterdam, The Netherlands
11.30 - 11.50 Targeting the tumour microenvironment through co-neutralization of IL-1beta and PD-1 to attenuate MRD
Ron-Nathan Apte, Beer Sheva, Israel
11.50 - 12.10 Targeting immunosuppressive adenosine pathway in cancer
Rakesh Kumar, Gaithersburg, MD, USA
12.10 - 12.30 GARP-directed cancer immunotherapy: mechanisms and opportunities
Zihai Li, Columbus, OH, USA
12.30 – 12.45 Speaker 6 – from submitted abstracts
12.45 - 13.00 Speaker 7 – from submitted abstracts
13.00 - 13.15 Speaker 8 – from submitted abstracts
13.15 - 13.30 Best Poster Awards & Closing Remarks
Chair: Volkmar Nüssler
13.30 - 14.30 Lunch
